A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Abroad (travel likely)RecruitingPHASE3
Conditions
Pancreatic Cancer · Metastatic Pancreatic Cancer · Metastatic Pancreatic Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
- Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton, Fullerton, California, United States
- Baptist MD Anderson Cancer Institute, Jacksonville, Florida, United States
- Saint Elizabeth Medical Center, Inc. DBA St. Elizabeth Health Care, Edgewood, Kentucky, United States
- HealthPartners Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
- HealthPartners Cancer Center at Regions Hospital, Saint Paul, Minnesota, United States
- NYU Long Island Mineola, Mineola, New York, United States
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
- White Plains Hospital Center for Cancer Care - Oncology, White Plains, New York, United States
- Utah Cancer Specialists, Salt Lake City, Utah, United States
- UVA Emily Couric Cancer Center, Charlottesville, Virginia, United States
- Virginia Cancer Specialists, Fairfax, Virginia, United States
- Virginia Mason Franciscan Health - Virginia Mason Medical Center, Seattle, Washington, United States
- The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan